FBIO
Fortress Biotech, Inc.
There isn't enough reported data to score FBIO yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
FBIO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Unavailable | |
| Unavailable |
FBIO's revenue is currently healthy, and its profitability is stable. There isn't enough data to rate its cash flow and balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
FBIO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 0.7x | $2.01 | +0.8% |
| Current | 0.7x | $1.99 | — |
| Fair | 0.9x | $2.32 | +17% |
| Expensive | 1x | $2.77 | +39% |
Historical ranges are pointers, not guarantees.
FBIO has the edge over NVO in the historical PE scenario, which offers more potential upside but is not a forecast.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
FBIO Forward outlook
There aren't enough analyst estimates for FBIO to show an outlook.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
FBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $2.70 | +$3.66 |
| Q1 2026 | $3.23 | +$5.37 |
| Q4 2025 | -$0.07 | +$2.62 |
| Q3 2023 | -$12.19 | +$3.56 |
| Q2 2023 | -$15.00 | +$0.90 |
| Q1 2023 | -$15.00 | -$2.10 |
| Q4 2022 | -$14.55 | -$2.70 |
| Q3 2022 | -$15.75 | -$8.55 |
FBIO has returned to profit: it earned $2.70 per share over the past year, after losing money the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over FBIO on earnings, with more consistent year-over-year improvement.
FBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $18.7M | +14% |
| Q1 2026 | $16M | +22% |
| Q4 2025 | $16.1M | +6.3% |
| Q3 2025 | $17.6M | +21% |
| Q2 2025 | $16.4M | +10% |
| Q1 2025 | $13.1M | +0.8% |
| Q4 2024 | $15.1M | -24% |
| Q3 2024 | $14.6M | -58% |
FBIO's revenue is recovering but still below its 2023 peak: $19M last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -53% | +169 points |
| Q1 2026 | -48% | +122 points |
| Q4 2025 | -30% | +128 points |
| Q3 2025 | -39% | +112 points |
| Q2 2025 | -222% | -36 points |
| Q1 2025 | -170% | +111 points |
| Q4 2024 | -158% | -59 points |
| Q3 2024 | -151% | -111 points |
FBIO's operating margin was −53% last quarter, up 169 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over FBIO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over FBIO on profitability, with a higher operating margin.
FBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | $203.9M | +$223.4M |
| Q4 2025 | -$12.5M | +$363K |
| Q3 2025 | -$6.1M | +$13.9M |
| Q1 2025 | -$19.6M | +$5.8M |
| Q4 2024 | -$12.9M | +$22.1M |
| Q3 2024 | -$20.1M | -$3.3M |
| Q1 2024 | -$25.4M | +$17.8M |
| Q4 2023 | -$35M | +$13M |
FBIO has the stronger cash trend. Its trailing FCF is up 243% versus its history, compared with NVO at down 14%.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
FBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -17% | -6.6M shares |
| 1 year | +6.6% | +2M shares |
| 3 years | +437% | +25.9M shares |
| 5 years | +527% | +26.7M shares |
FBIO has 32M diluted shares, up 6.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over FBIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
FBIO Net Leverage
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
FBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.7 | Neutral |
| Stochastic | 8.6 | Oversold |
FBIO's weekly RSI is 38 (neutral) and its Stochastic is 9 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
FBIO PE vs Healthcare Sector
| Metric | FBIO | Sector median | Relative |
|---|---|---|---|
| PE | 0.7x | 26x | 97% below |
| PE % | 15 | 29 | 14 pts below |
FBIO has the edge over NVO on valuation relative to its sector.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
FBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.00 | 0.5% below |
| 20 week MA | $2.56 | 22% below |
| 50 week MA | $2.84 | 30% below |
| 100 week MA | $2.49 | 20% below |
| 200 week MA | $3.62 | 45% below |
FBIO is in a downtrend: it's below all five of its weekly moving averages, and 45% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over FBIO on trend strength, trading above more of its moving averages.
FBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $37.1 | $51.5 | +39% |
| 2021 | $51.5 | $39.3 | -24% |
| 2022 | $39.3 | $8.25 | -79% |
| 2023 | $8.25 | $3.01 | -64% |
| 2024 | $3.01 | $2.36 | -22% |
| 2025 | $2.36 | $3.74 | +58% |
| 2026 YTD | $3.74 | $1.99 | -47% |
FBIO has finished lower in four of the last six years. It's down 47% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over FBIO on returns for 2026, with the stronger performance.